Market accessOfficial

Merck Sharp & Dohme plans permanent withdrawal of EMEND aprepitant capsules across EU/EEA

🇬🇷 EOF · Mon 09 Nov 2026

Greece's EOF has published a notice that the marketing authorisation holder will permanently stop marketing EMEND (aprepitant), with Greece named among the affected countries.

Greece's national medicines organisation, EOF, published a notice on 9 November 2026 about the planned permanent discontinuation of EMEND (aprepitant). The notice relays information from Merck Sharp & Dohme B.V., the marketing authorisation holder.

According to EOF, the company is stopping commercial supply of EMEND in all EU/EEA countries, Greece included. The notice title refers to the 125 mg and 80 mg hard capsules.

The text on EOF's page is brief. It does not give a reason for the decision, a withdrawal date or any alternative treatment arrangements. It points readers to a letter from Merck Sharp & Dohme B.V. addressed to healthcare professionals, which is available through a link on the EOF page.

What it means for your team

  • Read the company's letter to healthcare professionals, linked from the EOF notice, for the timing, reasons and any transition advice, which the EOF text does not give.
  • Regulatory and market-access teams should check how the withdrawal affects the national authorisation status and the availability of aprepitant products in their markets.
  • Quality and supply-chain teams should plan for stock and continuity of supply once the timeline is confirmed.
  • Pharmacovigilance teams should find out whether the letter sets out any communication steps for prescribers or patients.

Official source: EOF ↗

Article written by VigiEye from the official source (EOF). AI-assisted; check the source before acting.

More Market access All →